Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 137 B, Issue 1, 2005, Pages 1-4

  Tan, Eng King ^a   Cheah, Sin Yun ^a   Fook Chong, Stephanie ^a   Yew, Kenneth ^a   Chandran, V R ^a   Lum, Sau Ying ^a   Yi, Zhao ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

COMT variant; Parkinson's disease; Pyridoxine

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CYANOCOBALAMIN; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; LEVODOPA; NEUROFORTE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; THIAMINE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DIETARY INTAKE; DISEASE DURATION; DRUG MEGADOSE; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HOMOZYGOTE; HUMAN; MALE; MOTOR PERFORMANCE; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; DOPA DECARBOXYLASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PSYCHOMOTOR PERFORMANCE; PYRIDOXINE; TREATMENT OUTCOME; VARIATION (GENETICS); VITAMIN B COMPLEX;

EID: 23044509660     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30198     Document Type: Article

References (15)

1. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. 2003. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23:2008-2013.
2. Borglum AD, Bruun TG, Kjeldsen TE, et al. 1999. Two novel variants in the DOPA decarboxylase gene: Association with bipolar affective disorder. Mol Psychiatry 4:545-551.
3. Duvoisin RC, Yahr MD, Cote LD. 1969. Pyridoxine reversal of L-dopa effects in Parkinsonism. Trans Am Neurol Assoc 94:81-84.
4. Fahn S. 1974. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 24:431-441.
5. Jankovic J. 2000. Complications and limitations of drug therapy for Parkinson's disease. Neurology 55(12 Suppl 6):S2-S6.
6. Klawans HL, Ringel SP, Shenker DM. 1971. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor. J Neurol Neurosurg Psychiatry 34:682-686.
7. Lee CG, Tang K, Cheung YB, et al. 2004. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 41(5):e60.
8. Mannisto PT, Kaakkola S. 1999. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
9. Mars H. 1974. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions. Arch Neurol 30:444-447.
10. Mars H. 1975. Effect of chronic levodopa treatment on pyridoxine metabolism. Neurology 25:263-266.
11. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. 2000. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55(4):533-538.
12. Tan EK, Chai A, Lum SY, et al. 2003. Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population. Am J Med Genet B Neuropsychiatr Genet 120(1):58-62.
13. Tan EK, Chai A, Teo YY, et al. 2004. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62(1):128-131.
14. Wu RM, Cheng CW, Chen KH, et al. 2001. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology 56(3):375-382.
15. Yahr MD, Duvoisin RC. 1972. Pyridoxine and levodopa in the treatment of Parkinsonism. JAMA 220:861.